|
1
|
Tarrant JM, Robb L, van Spriel AB and
Wright MD: Tetraspanins: molecular organisers of the leukocyte
surface. Trends Immunol. 24:610–617. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zoller M: Tetraspanins: push and pull in
suppressing and promoting metastasis. Nat Rev Cancer. 9:40–55.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nakamoto T, Murayama Y, Oritani K, et al:
A novel therapeutic strategy with anti-CD9 antibody in gastric
cancers. J Gastroenterol. 44:889–896. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ghani FI, Yamazaki H, Iwata S, et al:
Identification of cancer stem cell markers in human malignant
mesothelioma cells. Biochem Biophys Res Commun. 404:735–742. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Milano MT and Zhang H: Malignant pleural
mesothelioma: a population-based study of survival. J Thorac Oncol.
5:1841–1848. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kobayashi N, Toyooka S, Yanai H, et al:
Frequent p16 inactivation by homozygous deletion or methylation is
associated with a poor prognosis in Japanese patients with pleural
mesothelioma. Lung Cancer. 62:120–125. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nojiri S, Gemba K, Aoe K, et al: Survival
and prognostic factors in malignant pleural mesothelioma: a
retrospective study of 314 patients in the west part of Japan. Jpn
J Clin Oncol. 41:32–39. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gaafar R, Bahnassy A, Abdelsalam I, et al:
Tissue and serum EGFR as prognostic factors in malignant pleural
mesothelioma. Lung Cancer. 70:43–50. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rena O, Boldorini LR, Gaudino E and
Casadio C: Epidermal growth factor receptor overexpression in
malignant pleural mesothelioma: prognostic correlations. J Surg
Oncol. 104:701–705. 2011. View Article : Google Scholar
|
|
10
|
Hirayama N, Tabata C, Tabata R, et al:
Pleural effusion VEGF levels as a prognostic factor of malignant
pleural mesothelioma. Respir Med. 105:137–142. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tabata C, Hirayama N, Tabata R, et al: A
novel clinical role for angiopoietin-1 in malignant pleural
mesothelioma. Eur Respir J. 36:1099–1105. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pinton G, Brunelli E, Murer B, et al:
Estrogen receptor-beta affects the prognosis of human malignant
mesothelioma. Cancer Res. 69:4598–4604. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fischer JR, Ohnmacht U, Rieger N, et al:
Promoter methylation of RASSF1A, RARbeta and DAPK predict poor
prognosis of patients with malignant mesothelioma. Lung Cancer.
54:109–116. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pass HI, Goparaju C, Ivanov S, et al:
hsa-miR-29c* is linked to the prognosis of malignant
pleural mesothelioma. Cancer Res. 70:1916–1924. 2010.
|
|
15
|
Travis W, Brambilla E, Müller-Hermelink H
and Harris C: World Health Organization Classification of Tumours:
Pathology & Genetics. Tumours of the Lung, Pleura, Thymus and
Heart. IARC Press; Lyon: 2004
|
|
16
|
Amatya VJ, Takeshima Y, Kushitani K,
Yamada T, Morimoto C and Inai K: Overexpression of CD26/DPPIV in
mesothelioma tissue and mesothelioma. Oncol Rep. 26:1369–1375.
2011.PubMed/NCBI
|
|
17
|
Ikeyama S, Koyama M, Yamaoko M, Sasada R
and Miyake M: Suppression of cell motility and metastasis by
transfection with human motility-related protein (MRP-1/CD9) DNA. J
Exp Med. 177:1231–1237. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Miyake M, Koyama M, Seno M and Ikeyama S:
Identification of the motility-related protein (MRP-1), recognized
by monoclonal antibody M31–15 which inhibits cell motility. J Exp
Med. 174:1347–1354. 1991.PubMed/NCBI
|
|
19
|
Higashiyama M, Doi O, Kodama K, et al:
Immunohistochemically detected expression of motility-related
protein-1 (MRP-1/CD9) in lung adenocarcinoma and its relation to
prognosis. Int J Cancer. 74:205–211. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mori M, Mimori K, Shiraishi T, et al:
Motility related protein 1 (MRP1/CD9) expression in colon cancer.
Clin Cancer Res. 4:1507–1510. 1998.PubMed/NCBI
|
|
21
|
Jamil F, Peston D and Shousha S: CD9
immunohistochemical staining of breast carcinoma: unlikely to
provide useful prognostic information for routine use.
Histopathology. 39:572–577. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sho M, Adachi M, Taki T, et al:
Transmembrane 4 superfamily as a prognostic factor in pancreatic
cancer. Int J Cancer. 79:509–516. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang JC, Begin LR, Berube NG, et al:
Down-regulation of CD9 expression during prostate carcinoma
progression is associated with CD9 mRNA modifications. Clin Cancer
Res. 13:2354–2361. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Okochi H, Mine T, Nashiro K, Suzuki J,
Fujita T and Furue M: Expression of tetraspans transmembrane family
in the epithelium of the gastrointestinal tract. J Clin
Gastroenterol. 29:63–67. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Buim ME, Lourenco SV, Carvalho KC, et al:
Downregulation of CD9 protein expression is associated with
aggressive behavior of oral squamous cell carcinoma. Oral Oncol.
46:166–171. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mhawech P, Herrmann F, Coassin M, Guillou
L and Iselin CE: Motility-related protein 1 (MRP-1/CD9) expression
in urothelial bladder carcinoma and its relation to tumor
recurrence and progression. Cancer. 98:1649–1657. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Higashiyama M, Taki T, Ieki Y, et al:
Reduced motility related protein-1 (MRP-1/CD9) gene expression as a
factor of poor prognosis in non-small cell lung cancer. Cancer Res.
55:6040–6044. 1995.PubMed/NCBI
|
|
28
|
Kohmo S, Kijima T, Otani Y, et al: Cell
surface tetraspanin CD9 mediates chemoresistance in small cell lung
cancer. Cancer Res. 70:8025–8035. 2010. View Article : Google Scholar : PubMed/NCBI
|
